{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:58:22Z","timestamp":1791374302531,"version":"4.3.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacl.2025.10.062","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:32:36Z","timestamp":1761186756000},"page":"44-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies"],"prefix":"10.1016","volume":"20","author":[{"given":"Manuel","family":"Castro Cabezas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattea","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-0999","authenticated-orcid":false,"given":"Jos\u00e9","family":"Tu\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-1926","authenticated-orcid":false,"given":"Michal","family":"Vrabl\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7553-9543","authenticated-orcid":false,"given":"Hagai","family":"Tavori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Perrone-Filardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.10.062_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028892","article-title":"Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum","volume":"12","author":"Wilkinson","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.10.062_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0004","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0005","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0006","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.10.062_bib0009","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2023.8646","article-title":"Low-density lipoprotein cholesterol levels in adults with coronary artery disease in the US, January 2015 to March 2020","volume":"330","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.10.062_bib0011","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.10.062_bib0012","article-title":"Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins","volume":"10 - 2023","author":"Vijayaraghavan","year":"2024","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.jacl.2025.10.062_bib0013","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0014","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jacl.2020.07.009","article-title":"Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial","volume":"14","author":"Roth","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials","volume":"223","author":"Farnier","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0016","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.062_bib0017","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jacl.2019.04.005","article-title":"PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: a pooled analysis of nine randomized-controlled studies of alirocumab","volume":"13","author":"Bruckert","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0018","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.062_bib0019","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.062_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.062_bib0021","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0022","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.10.062_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fca.14.82","article-title":"ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks","volume":"11","author":"Roth","year":"2015","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0025","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.062_bib0026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2025.10.062_bib0027","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacl.2025.10.062_bib0028","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0029","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2025.10.062_bib0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.10.062_bib0031","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2025.10.062_bib0032","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.10.062_bib0033","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.062_bib0034","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/eurheartj\/ehac544.1412","article-title":"Prevalence of reaching target low-density lipoprotein cholesterol (LDL-C) in very high-risk patients using high intensity lipid-modifying therapy","volume":"43","author":"Omar Khader","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0035","article-title":"PCSK9 inhibitors for acute coronary syndrome: the era of early implementation","volume":"10","author":"Chen","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.10.062_bib0036","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.062_bib0037","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00392-006-0403-x","article-title":"Low density lipoprotein cholesterol, statins and cardiovascular events: a meta\u2013analysis","volume":"95","author":"Genser","year":"2006","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacl.2025.10.062_bib0038","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.062_bib0039","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14740\/cr1224","article-title":"Effect of ezetimibe added to high-intensity statin therapy on low-density lipoprotein cholesterol levels: a meta-analysis","volume":"12","author":"Lee","year":"2021","journal-title":"Cardiol Res"},{"key":"10.1016\/j.jacl.2025.10.062_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180869","article-title":"Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin\/kexin type 9","volume":"12","author":"Romagnuolo","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jacl.2025.10.062_bib0041","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 association with lipoprotein(a)","volume":"119","author":"Tavori","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2025.10.062_bib0042","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacl.2025.10.062_bib0043","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/dom.13960","article-title":"A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus","volume":"22","author":"Burggraaf","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacl.2025.10.062_bib0044","unstructured":"Food and Drug Adminstration, Praulent prescribing information. Accessed date, 12 November 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125559s002lbl.pdf, 2017."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:46:18Z","timestamp":1791373578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425004829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1933287425004829"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.062","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of alirocumab in patients with established atherosclerotic vascular disease before the first cardiovascular event: Pooled analysis of phase 3 ODYSSEY studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}